Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05032339 · ClinicalTrials.gov registry record
Evaluation of the Plasma Cell Disorders Panel on the BD FACSLyric™ Flow Cytometer
A clinical trial, sponsored by Becton, Dickinson and Company.
- Completed
- Registry status
- 208
- Enrollment target
NCT05032339: Completed study, sponsored by Becton, Dickinson and Company.
NCT05032339 is a clinical trial that has completed, run by Becton, Dickinson and Company. The registered enrollment target is 208 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05032339 has completed, sponsored by Becton, Dickinson and Company.
- COMPLETED
- Registry status
- 208 participants
- Enrollment target
Study Summary
Multi-site, prospective performance study to determine equivalency between the investigational OneFlow PCD panel on the FACSLyric system versus the final clinical diagnosis.
Primary Outcome
Determine equivalence between the investigational OneFlow PCD Panel on FACSLyric system results analyzed by two independent experts versus the final clinical diagnosis for normal polyclonal plasma cells or abnormal plasma cells using leftover, hematologically abnormal specimens. Sensitivity and specificity will be calculated .
Interventions
- DIAGNOSTIC_TEST IUO Plasma Cell Disorders Panel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 208 participants |
| Start Date | 2021-05-04 |
| Est. Completion | 2023-10-25 |
What the finished NCT05032339 record still lists
NCT05032339 is an observational study that tracks outcomes without assigning an intervention. The registered 208 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which IUO Plasma Cell Disorders Panel is the first listed.
NCT05032339 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05032339 about?
NCT05032339 is a clinical study titled "Evaluation of the Plasma Cell Disorders Panel on the BD FACSLyric™ Flow Cytometer". Multi-site, prospective performance study to determine equivalency between the investigational OneFlow PCD panel on the FACSLyric system versus the final clinical diagnosis.
What is the current status of trial NCT05032339?
This trial is currently completed. The enrollment target is 208 participants. The study started on 2021-05-04. Estimated completion is 2023-10-25.
What interventions are being tested in trial NCT05032339?
The interventions under investigation include: IUO Plasma Cell Disorders Panel (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05032339?
This trial is sponsored by Becton, Dickinson and Company, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465774 · 208 participants
Indwelling Pleural Catheters With or Without Doxycycline in Treating Patients With Malignant Pleural Effusions
- NCT03803332 · 208 participants · NA
A Trial Comparing Interpersonal Therapy to Exposure Therapy for PTSD Due to Military Sexual Trauma (MST) in Male and Female Military Personnel
- NCT04732065 · 208 participants · Phase 1
ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors
- NCT05293756 · 208 participants · NA
OPtimizing Technology to Improve Medication Adherence and BP Control (OPTIMA-BP)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI